CenterBook Partners LP Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

CenterBook Partners LP increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 307.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 48,464 shares of the biopharmaceutical company’s stock after purchasing an additional 36,556 shares during the quarter. CenterBook Partners LP’s holdings in Catalyst Pharmaceuticals were worth $1,131,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CPRX. Royal Bank of Canada lifted its position in Catalyst Pharmaceuticals by 39.1% during the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock worth $5,177,000 after buying an additional 60,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Catalyst Pharmaceuticals by 5.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock worth $1,749,000 after buying an additional 3,800 shares during the period. Goldman Sachs Group Inc. lifted its position in Catalyst Pharmaceuticals by 11.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after buying an additional 333,100 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Catalyst Pharmaceuticals by 99.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after buying an additional 262,392 shares during the period. Finally, Intech Investment Management LLC grew its holdings in Catalyst Pharmaceuticals by 6.5% in the first quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock valued at $1,700,000 after purchasing an additional 4,261 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CPRX has been the topic of a number of recent analyst reports. Stephens set a $32.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Robert W. Baird cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $31.34 on Thursday. The company has a market cap of $3.84 billion, a PE ratio of 18.01, a P/E/G ratio of 0.95 and a beta of 0.74. The company’s fifty day simple moving average is $28.89 and its 200-day simple moving average is $25.53. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).